The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 GTx Inc.  (GTXI) Trade Now »     Rate GTXI  -  Discuss GTXI  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:
N/A

** not enough data to be rated 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate GTXI:



GTXI Analysis & Videos »


GTXI: Bull or Bear?

BioMedReports FDA Calendar: Seven Laggard Trades Graphic_rating_buy GTXI
Mikerun
73%
 -56.55%
in 147 days
Below are seven companies from the <font> BioMedReports.com FDA Calendar </font> database of over 200 entries, which have pending new drug decision(s) at the FDA combined with a stock price that is below its 200-day moving average (200-DMA). The list includes a balanced mix of two large-caps, two mid-caps, and three small-cap stocks which have been laggards in the overall market rally with looming regulatory catalysts in the form of FDA new drug decisions serving as potential upside catalysts. Data Source: Yahoo! Finance on 6/17/09 during late day trading.
 
<> <font> <>http...
By  Mike Havrilla   (+1.04%  risk: conservative)  06/17/09 Comment


FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx Graphic_rating_buy GTXI
Mikerun
73%
 -11.08%
in 55 days
(closed on 06/17/09)
Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars .
 
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
By  Mike Havrilla   (+1.04%  risk: conservative)  04/23/09 Comment


Bullish on GTXI ... Graphic_rating_buy GTXI
Foto
62%
 -64.42%
in 212 days
Estimated Holding Period: 1-3 months Profile: GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions in the United States. The company markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. Its product candidates in clinical development include ACAPODENE, a selective estrogen receptor modulator, which is in pivotal Phase III clinical trials for...
By  Marian Filo   (-24.55%  risk: aggressive)  04/13/09 Comment


Get free stock alert for GTXI:
Your Email Address:





People Bullish on GTXI

Gino Cicero
Analyst
N/A
16 days ago

Mikerun
Mike Havrilla
Principal
73%
4 mos ago

Foto
Marian Filo
Principal
62%
7 mos ago

jmccormi@cisco.com
Analyst
68%
about 1 year ago

Art_037_-_copy
Art Craig
Analyst
30%
about 1 year ago


People Bearish on GTXI

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.56% 370
2 Gerald Greene 18.14 +69.43% 207
3 stockmarketfunding.com 17.66 +25.71% 53
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +75.75% 34


POPULAR STOCKS
Symbol Company Name Sentiment
DRYS DryShips Inc.
SIRI Sirius Satellite Radio Inc
C Citigroup Inc
GE General Electric Company
CSCO Cisco Systems Inc
BA The Boeing Company

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on GTXI


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About GTx Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch